Oral ferroportin inhibitor VIT‐2763: First‐in‐human, phase 1 study in healthy volunteers

por Richard, Frank, van Lier, Jan Jaap, Roubert, Bernard, Haboubi, Teba, Göhring, Udo‐Michael, Dürrenberger, Franz
Publicado 2019